The Business of Biofabrication

London, UK — Mytos has officially launched its automated CDMO (Contract Development and Manufacturing Organization), powered by the company’s proprietary iDEM™ automation platform, with a mission to tackle one of regenerative medicine’s enduring challenges: the scalable, cost-efficient manufacturing of stem cell–derived therapies.

Operating within the CGT Catapult’s Stevenage Manufacturing Innovation Centre, Mytos’ new facility aims to deliver both autologous and allogeneic cell therapy production at unprecedented scale. By September 2026, the company projects capacity for up to 1,500 autologous doses or 25,000 allogeneic doses annually, with plans for future expansion.

Picture From Mytos Website

A Breakthrough in Automated Manufacturing

Traditional cell therapy manufacturing remains highly manual—labor-intensive, variable, and expensive. Mytos’ automation-driven approach streamlines these processes, reducing human error and batch-to-batch variability, while improving GMP compliance and tech transfer speed.

According to Felix Q., Senior Director of Business Development, this shift represents more than an operational upgrade. It’s a move toward democratizing access to advanced therapies by eliminating long-standing manufacturing bottlenecks.

“We’re combining Mytos’ engineering excellence with CGT Catapult’s infrastructure and regulatory know-how to bring advanced therapies to more patients, faster,” said Felix.

Strategic Collaboration

The partnership between Mytos and CGT Catapult integrates world-class automation with regulatory and infrastructure expertise. Together, they aim to set a new standard for scalable, automated, and quality-driven cell therapy production, positioning the UK as a leader in regenerative medicine manufacturing.

---

About Mytos
Mytos is an automation company focused on transforming the way cell therapies are manufactured. Its iDEM™ platform integrates robotics, process analytics, and digital traceability to streamline cell culture, differentiation, and expansion workflows across the cell therapy development pipeline.

About CGT Catapult
The Cell and Gene Therapy Catapult (CGT Catapult) is a UK government-supported innovation center dedicated to advancing the development, scale-up, and commercialization of cell and gene therapies.